Administered in Green Bay
HEMGENIX is revolutionizing treatment with its groundbreaking one-time infusion that offers elevated and sustained factor IX levels for years. Approved by the FDA in 2022, HEMGENIX has been the focus of extensive research for many years, promising new hope for patients.
We are thrilled to highlight a significant achievement within our team. Andrea Buxton, APNP, one of HOC’s Nurse Practitioners, recently shared her invaluable insights on the preparation and administration experiences for the first two patients to be commercially dosed with HEMGENIX. Her contributions are not only a testament to her expertise but also underscore the innovative spirit that drives our organization.
For more information check out the FAQ’s from HEMGENIX website:
.
